Advertisement

AAPS PharmSciTech

, Volume 19, Issue 5, pp 2322–2329 | Cite as

A Novel Colon-Specific Osmotic Pump Capsule of Panax notoginseng Saponins (PNS): Formulation, Optimization, and In Vitro-In Vivo Evaluation

  • Dong Jin
  • Bin Wang
  • Rongfeng Hu
  • Dan Su
  • Jiayi Chen
  • Hong Zhou
  • Wenjie Lu
  • Yuxing Guo
  • Wenyou Fang
  • Song Gao
Research Article
  • 103 Downloads

Abstract

In the current study, a novel colon-specific osmotic pump capsule of Panax notoginseng saponins was developed to achieve colon-specific release, a zero-order, thus to promote the efficacy of Panax notoginseng saponins. The capsule was assembled using a semi-permeable capsule shell with contents including Panax notoginseng saponins, sodium chloride (NaCl), and Ludipress. The semipermeable membrane was made of cellulose acetate (CA), along with polyethylene glycol (PEG) 6000 for flexibility and strength, and Eudragit® S100 for colon-specific targeting. The in vitro dissolution test showed an approximately zero-order release of Panax notoginseng saponins over 12 h at pH 7.8 through the pores on the membrane. Meanwhile, the drug release from the optimal formulation was found to be independent of equipment type or agitation speed. Rather, it depended on mainly the osmotic pressure of the dissolution media. The in vivo test in beagle dogs demonstrated that the relative bioavailability of the current system was 487.42% in comparison to that of the marketed product, yet with a prolonged retention time. The novel controlled delivery system for Panax notoginseng saponins in the current study utilizing colon-specific and osmotic pump system therefore offered the advantages of avoiding stomach and enteric irritation, reducing dosage frequency, minimizing the drug fluctuation in plasma, and improving its oral bioavailability.

KEY WORDS

Panax notoginseng saponins colon-specific osmotic pump capsule pharmacokinetics 

Notes

Acknowledgements

We thank Dr. Jun Shao of St. John’s University for his support in the design and writing of the thesis.

Funding Information

This project was supported by the National Natural Science Foundation of China (No.81573615, No.81274100) and Project of Scientific Research Fund of Anhui University of Chinese medicine (No. 2016zr009).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Wang D, Jie Q, Liu B, Li Y, Dai L, Luo J, et al. Saponin extract from panax notoginseng promotesangiogenesis through ampk and enosdependent pathways in huvecs. Mol Med Rep. 2017;16(4):5211–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Li Y, Zhang Y, Zhu CY. Pharmacokinetics and correlation between in vitro release and in vivo absorption of bio-adhesive pellets of panax notoginseng saponins. Chin J Nat Med. 2017;15(2):142–51.PubMedGoogle Scholar
  3. 3.
    Song H, Wang P, Liu J, Wang C. Panax notoginseng preparations for unstable angina pectoris: a systematic review and meta-analysis. Phytother Res. 2017;31(8):1162–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Pang HH, Li MY, Wang Y, Tang MK, Ma CH, Huang JM. Effect of compatible herbs on the pharmacokinetics of effective components of panax notoginseng in fufang xueshuantong capsule. J Zhejiang Univ Sci B. 2017;18(4):343–52.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Duan L, Xiong X, Hu J, Liu Y, Li J, Wang J. Panax notoginseng saponins for treating coronary artery disease: a functional and mechanistic overview. Front Pharmacol. 2017;8:1–18.Google Scholar
  7. 7.
    Chen YM, Li YW, Zhu GH. Panax notoginseng saponins injection induced 103 cases of adverse reactions analysis. Chin J Chin Mater Med. 2010;35(2):237–9.Google Scholar
  8. 8.
    Banerjee A, Pathak S, Subramanium VD, G D, Murugesan R, Verma RS. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today. 2017;22(8):1224–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Vong LB, Mo J, Abrahamsson B, Nagasaki Y. Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose-response efficacy. J Control Release. 2015;210:19–25.CrossRefPubMedGoogle Scholar
  10. 10.
    Chaudhary A, Tiwari N, Jain V, Singh R. Microporous bilayer osmotic tablet for colon-specific delivery. Eur J Pharm Biopharm. 2011;78(1):134–40.CrossRefPubMedGoogle Scholar
  11. 11.
    SSDaG V. Rational design and development of colon-specific prodrugs. Curr Top Med Chem. 2011;11:2318–45.CrossRefGoogle Scholar
  12. 12.
    Jin L, Ding YC, Zhang Y, Xu XQ, Cao Q. A novel ph-enzyme-dependent mesalamine colon-specific delivery system. Drug Des Devel Ther. 2016;10:2021–8.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Sanjay K, Jain AJ. Target specific drug release to the colon. Expert Opin Drug Deliv. 2008;5(5):483–98.CrossRefGoogle Scholar
  14. 14.
    Ruiz JF, Kedziora K, Windle H, Kelleher DP, Gilmer JF. Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models. J Pharm Pharmacol. 2011;63(6):806–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Wen P, Feng K, Yang H, Huang X, Zong MH, Lou WY, et al. Electrospun core-shell structured nanofilm as a novel colon-specific delivery system for protein. Carbohydr Polym. 2017;169:157–66.CrossRefPubMedGoogle Scholar
  16. 16.
    Patel MM. Colon targeting: an emerging frontier for oral insulin delivery. Expert Opin Drug Deliv. 2013;10(6):731–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Fang WY. Studies on oral colon-specific capsules of panax notoginsens saponins liposomes [master]: Anhui University of Chinese Medicine. 2015.Google Scholar
  18. 18.
    Xie Y, Lu Y, Qi J, Li X, Zhang X, Han J, et al. Synchronized and controlled release of multiple components in silymarin achieved by the osmotic release strategy. Int J Pharm. 2013;441(1–2):111–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Liu X, Wang S, Chai L, Zhang D, Sun Y, Xu L, et al. A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques. Int J Pharm. 2014;461(1–2):529–39.CrossRefPubMedGoogle Scholar
  20. 20.
    Pan H, Jing H, Yang X, Pan W, Chen T. Synchronized and controlled release of metformin hydrochloride/glipizide from elementary osmotic delivery. Drug Dev Ind Pharm. 2017;43(5):780–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Wu L, LI HY, YIN XZ, LI Y, CHEN JX, HU RF, et al. Applicability of a natural swelling matrix as the propellant of osmotic pump tablets. Acta Pharm Sin. 2013;48(08):1319–24.Google Scholar
  22. 22.
    Liu D, Yu S, Zhu Z, Lyu C, Bai C, Ge H, et al. Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation. Int J Pharm. 2014;475(1–2):496–503.CrossRefPubMedGoogle Scholar
  23. 23.
    Banerjee A, Verma PR, Gore S. Controlled porosity solubility modulated osmotic pump tablets of gliclazide. AAPS PharmSciTech. 2015;16(3):554–68.CrossRefPubMedGoogle Scholar
  24. 24.
    Zeng QP, Liu ZH, Huang AW, Zhang J, Song HT. Preparation and characterization of silymarin synchronized-release microporous osmotic pump tablets. Drug Des Devel Ther. 2016;10:519–31.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Waterman KC, Goeken GS, Konagurthu S, Likar MD, MacDonald BC, Mahajan N, et al. Osmotic capsules: a universal oral, controlled-release drug delivery dosage form. J Control Release. 2011;152(2):264–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Li S, Wang X, Wang Y, Zhao Q, Zhang L, Yang X, et al. A novel osmotic pump-based controlled delivery system consisting of ph-modulated solid dispersion for poorly soluble drug flurbiprofen: in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2015;41(12):2089–99.CrossRefPubMedGoogle Scholar
  27. 27.
    Guan J, Zhou L, Pan Y, Han H, Xu H, Pan W. A novel gastro-retentive osmotic pump capsule using asymmetric membrane technology: in vitro and in vivo evaluation. Pharm Res. 2010;27(1):105–14.CrossRefPubMedGoogle Scholar
  28. 28.
    Hill A, Geissler S, Weigandt M, Mader K. Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics. J Control Release. 2012;158(3):403–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Bhatt B, Kumar V. Regenerated cellulose capsules for controlled drug delivery: part iii. Developing a fabrication method and evaluating extemporaneous utility for controlled-release. Eur J Pharm Sci. 2016;91:40–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Bhatt B, Kumar V. Regenerated cellulose capsules for controlled drug delivery: part iv. In-vitro evaluation of novel self-pore forming regenerated cellulose capsules. Eur J Pharm Sci. 2017;97:227–36.CrossRefPubMedGoogle Scholar
  31. 31.
    Bhatt B, Kumar V. Regenerated cellulose capsules for controlled drug delivery, part 2: modulating membrane permeability by incorporation of depolymerized cellulose and altering membrane thickness. J Pharm Sci. 2015;104(12):4266–75.CrossRefPubMedGoogle Scholar
  32. 32.
    Viness Pillay RF. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. J Control Release. 1998;55:45–55.CrossRefGoogle Scholar
  33. 33.
    Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–96.CrossRefPubMedGoogle Scholar
  34. 34.
    Guo Q, Li P, Wang Z, Cheng Y, Wu H, Yang B, et al. Brain distribution pharmacokinetics and integrated pharmacokinetics of panax notoginsenoside r1, ginsenosides rg1, rb1, re and rd in rats after intranasal administration of panax notoginseng saponins assessed by uplc/ms/ms. J Chromatogr B. 2014;969:264–71.CrossRefGoogle Scholar
  35. 35.
    Wu H, Liu H, Bai J, Lu Y, Du S. Simultaneous determination of notoginsenoside r1, ginsenoside rg1, ginsenoside re and 20(s) protopanaxatriol in beagle dog plasma by ultra high performance liquid mass spectrometry after oral administration of a panax notoginseng saponin preparation. J Chromatogr B. 2015;974:42–7.CrossRefGoogle Scholar
  36. 36.
    Khan ZA, Tripathi R, Mishra B. Floating elementary osmotic pump tablet (feopt) for controlled delivery of diethylcarbamazine citrate: a water-soluble drug. AAPS PharmSciTech. 2011;12(4):1312–23.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Dong Jin
    • 1
  • Bin Wang
    • 1
  • Rongfeng Hu
    • 1
    • 2
  • Dan Su
    • 3
  • Jiayi Chen
    • 4
  • Hong Zhou
    • 1
  • Wenjie Lu
    • 5
  • Yuxing Guo
    • 4
  • Wenyou Fang
    • 1
  • Song Gao
    • 1
  1. 1.Key Laboratory of Xin’an Medicine, Ministry of Education, Anhui Province, Key Laboratory of R&D of Chinese MedicineAnhui University of Chinese MedicineHefeiPeople’s Republic of China
  2. 2.Anhui Academy of Chinese Medicine Anhui “115” Xin’an Medicine Research & Development Innovation TeamHefeiPeople’s Republic of China
  3. 3.Department of PharmacyThe First Affiliated Hospital of University of Science and Technology of ChinaHefeiPeople’s Republic of China
  4. 4.Department of Pharmaceutical Sciences, College of pharmacy and Health SciencesSt. John’s UniversityNew YorkUSA
  5. 5.School of PharmacyChina Pharmaceutical UniversityNanjingPeople’s Republic of China

Personalised recommendations